What Is Adagen?

Adagen (pegademase bovine) Injection is a modified enzyme used for enzyme replacement therapy (ERT) for the treatment of severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase (ADA). Adagen received FDA approval in 1990 and has more than 20 years of proven clinical experience.1

Adagen is a conjugate of monomethoxypolyethylene glycol (PEG) covalently attached to the ADA enzyme. The ADA used in the manufacture of Adagen is derived from bovine intestine.1 PEG modification of the ADA molecule slows its clearance and reduces immunogenicity, allowing ADA to achieve its full therapeutic effect. On a volume basis, the ADA activity of pegademase is approximately 1800 times greater than that of erythrocytes.2 By maintaining a high level of ADA activity in plasma, Adagen eliminates extracellular Ado and dAdo, correcting the metabolic toxicity that impairs lymphocyte function.3

Adagen works by replacing ADA that is missing in these patients.1

Click here to access the Adagen Prescribing Infomation.

Please see the Important Safety Information below.

References: 1. Adagen [package insert]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals, Inc.; 2011. 2. Hershfield M. Combined immune deficiencies due to purine enzyme defects. In: Stiehm ER, Ochs HD, Winkelstein JA, eds. Immunologic Disorders in Infants & Children. 5th ed. Philadelphia, PA: Elsevier Saunders; 2004:480-504. 3. Hershfield M. Adenosine deaminase deficiency. GeneReviews. http://www.ncbi.nlm.nih.gov/books/NBK1483. Accessed March 8, 2011.